PeptideDeepDiveIpamorelin Peptide: Evidence, Side Effects & Legal Status (2026)
What is ipamorelin, how does it work, and what does the human evidence actually show? This guide separates its documented growth-hormone effects from the anti-aging and recovery claims commonly made online.
Ipamorelin is a growth-hormone secretagogue, not growth hormone itself. It has real pharmacology and some human clinical-trial history, but it is not FDA-approved, long-term safety data for the uses promoted online is lacking, and its better-known Phase II program was for postoperative ileus rather than anti-aging or muscle growth.
What Is Ipamorelin? A Pharmaceutical-Origin Peptide
Ipamorelin is a synthetic five-amino-acid peptide originally developed by Novo Nordisk, derived from an earlier compound called GHRP-1. It’s studied for stimulating the body’s own growth hormone release rather than supplying growth hormone directly.
How Ipamorelin Works: Ghrelin Receptor Signalling
Ipamorelin binds the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering a signaling cascade that causes pulsed release of stored growth hormone — mimicking how natural ghrelin works. Because it acts on the pituitary’s own GH reserves, it depends on a functioning pituitary, and the body’s natural feedback loops stay intact. For the related GHRH pathway, see our CJC-1295 guide.
Ipamorelin’s Main Differentiator: Hormone Selectivity
Ipamorelin’s defining feature, established in its original 1998 characterization, is selectivity: at GH-releasing doses, it doesn’t meaningfully raise cortisol, prolactin, or several other hormones — unlike older growth-hormone-releasing peptides such as GHRP-2 and GHRP-6. This is a genuine, well-documented distinction, not just marketing language. Our CJC-1295 vs. ipamorelin comparison explains how the two signalling approaches differ.
Ipamorelin Human Trials: Real Data, But Not for Anti-Aging
Ipamorelin has actual Phase II human trial data, which is more than many peptides in this space can claim. But that data comes from trials for postoperative ileus (a gut-motility condition after surgery), not from any anti-aging, muscle-building, or longevity indication. The program wasn’t advanced to Phase III, and no completed human efficacy trials exist for the uses it’s popularly marketed for today.
Ipamorelin Side Effects and Safety: What Is Known?
Commonly reported effects include mild headache and facial flushing. That said, growth hormone has insulin-antagonist effects, so GH secretagogues carry a theoretical risk of worsening insulin resistance. It’s specifically not recommended for anyone with active or recent cancer history, pregnancy, or pituitary axis disorders. For broader context on growth-hormone-related risk signals, read our growth hormone adverse-event overview.
Is Ipamorelin FDA Approved? Legal and WADA Status in 2026
As of April 2026, ipamorelin’s nomination to the FDA’s restricted Category 2 list for 503A compounding pharmacies was withdrawn — but it remains on the active Category 2 table for 503B outsourcing facilities, meaning that pathway stays prohibited. It has no FDA drug approval and no USP or NF monograph. Separately, ipamorelin is listed under the World Anti-Doping Agency’s 2026 Prohibited List (category S2), banned for competitive athletes both in and out of competition. If the regulatory distinction is unclear, see our FDA-approved vs. research peptides explainer.
Nomination withdrawn from Category 2 as of April 2026 — status now unresolved, not approved.
Still listed on the active Category 2 restricted table — this pathway remains prohibited.
Long-Term Ipamorelin Safety Data Is Still Missing
There’s no long-term human safety data for the GH-secretagogue uses ipamorelin is actually marketed for, no established dosing for those uses, and products sold online aren’t FDA-regulated or verified for purity — they may contain contaminants, incorrect concentrations, or misidentified compounds entirely.
Ipamorelin’s “cleaner” hormonal profile compared to older GH secretagogues is genuinely well-documented — that part of the marketing checks out. What doesn’t check out: its human trial history is for a discontinued gut-motility program, not the anti-aging and recovery uses it’s sold for today. It’s not FDA-approved, its 2026 compounding status is unresolved rather than cleared, and it’s a banned substance for competitive athletes.
Ipamorelin FAQ
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid growth-hormone secretagogue. It activates the ghrelin receptor and stimulates pulsed release of the body’s own growth hormone rather than supplying growth hormone directly.
Is ipamorelin FDA approved?
No. Ipamorelin is not FDA-approved for any use and has no USP or NF monograph. Its 2026 compounding status differs between the 503A and 503B pathways described above.
What human evidence exists for ipamorelin?
Ipamorelin reached Phase II human testing for postoperative ileus, but that program did not advance to Phase III. That evidence does not establish efficacy for anti-aging, muscle-building or longevity uses.
Is ipamorelin banned in sport?
Yes. Ipamorelin falls under the World Anti-Doping Agency’s prohibited category covering peptide hormones and growth-hormone secretagogues.
References
- Original 1998 pharmacological characterization of ipamorelin’s receptor selectivity and hormonal profile.
- Phase II clinical trial of ipamorelin for postoperative ileus, discontinued prior to Phase III advancement.
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (PCAC) materials on ipamorelin acetate and free base, 2026.
- U.S. Food and Drug Administration (2026) 503A and 503B Bulks Lists — Status of Nominated Bulk Drug Substances, April 2026 update.
- World Anti-Doping Agency (2026) Prohibited List, category S2 (Peptide Hormones, Growth Factors).